Legend:
CC = Baltimore Convention Center, H = Hilton Baltimore
* = applied session ! = JSM meeting theme
Activity Details
|
|
337 * !
|
Tue, 8/1/2017,
10:30 AM -
12:20 PM
|
CC-315
|
Interim Monitoring and Analyses: Two-Stage, Multi-Stage, and Group Sequential Designs — Contributed Papers
|
Biopharmaceutical Section
|
Chair(s): Mike Henderson, SAS
|
10:35 AM
|
Decision of Performing Interim Analysis for Comparative Clinical Trials
—
Kyongsun Pak, Kitasato University ; Susanna Jacobus, Dana Farber Cancer Institute ; Hajime Uno, Dana Farber Cancer Institute
|
10:50 AM
|
The Three Keys to Having Effective Interim Review Data Monitoring Committee Meetings for Clinical Trials
—
Navneet Hakhu, Axio Research
|
11:05 AM
|
Determination of Interim Go/No-Go Criteria with Simulations of Longitudinal Continuous Data in a Phase 2 Clinical Trial of a Neurodegenerative Disorder
—
Weining Z Robieson, AbbVie Inc. ; Greg Cicconetti, Abbvie ; Deli Wang, AbbVie, Inc.
|
11:20 AM
|
Robust Inference for Group Sequential Trials
—
Jitendra Ganju ; Yunzhi Lin, AbbVie ; Kefei Zhou, Theravance
|
11:35 AM
|
Strategies in Designing Interim Analyzes Under Discrete Random-Effects Model in a Multiregional Trial
—
Hsiao-Hui Tsou, National Health Research Institutes ; Chi-Tian Chen, National Health Research Institutes ; K. K. Gordon Lan, Janssen Pharmaceutical Companies of Johnson & Johnson ; Chin-Fu Hsiao, National Health Research Institutes
|
11:50 AM
|
Multi-Arm Multi-Stage Group Sequential Design in Clinical Trial
—
Pranab Ghosh, Cytel Inc, Boston University ; Cyrus Mehta, Cytel Inc
|
12:05 PM
|
Extension of the Two-Stage Randomized Trial Design for Testing Treatment, Self-Selection, and Treatment Preference Effects to Binary Outcomes
—
Briana Cameron, Yale University ; Denise Esserman, Yale School of Public Health ; Peter Peduzzi, Yale School of Public Health
|
|